KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Stuart C Gordon, Alejandra Villamil, Ira M Jacobson, Eric J Lawitz, Ziad Younes, Marina G Silveira, Christopher L Bowlus, Joost P H Drenth, John M Vierling, Ulrike Morgera, Adam Vasura, George Dalekos, Andrea Galli, Mordechai Rabinovitz, Jeong Heo, Frederik Nevens, Cynthia Levy, Yan Zhou, Susheela Carroll, Daria B Crittenden

Hepatol Commun 10(5) e0918

PMID41974026
PMCIDPMC13075930
DOI10.1097/HC9.0000000000000918
发表日期2026-04-13
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;FIGURE 1:图注未提示 KM 曲线;FIGURE 2:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Treatment options are limited for patients with primary biliary cholangitis (PBC) and cirrhosis. Seladelpar, a first-in-class delpar (selective PPAR-δ agonist), had generally similar efficacy and safety among patients with versus without compensated cirrhosis in the phase 3 RESPONSE study. Here we provide additional data on seladelpar in patients with compensated cirrhosis from the phase 3 program. METHODS: In RESPONSE, patients with PBC and an inadequate response or intolerance to UDCA were randomized 2:1 to seladelpar 10 mg or placebo for 1 year. Upon completion, patients rolled over into the open-label (seladelpar 10 mg) phase 3 ASSURE study, which also enrolled patients from earlier seladelpar legacy PBC studies. Here, we assessed the composite endpoint [alkaline phosphatase (ALP) <1.67×upper limit of normal (ULN), ALP decrease ≥15%, and total bilirubin ≤ULN], other laboratory changes, and safety in all patients with cirrhosis from RESPONSE and an interim analysis of the ongoing ASSURE study through January 2024. RESULTS: Twenty-seven patients with compensated cirrhosis enrolled in RESPONSE (18 seladelpar, 9 placebo). At month 12, 38.9% and 22.2% of patients in the seladelpar and placebo groups, respectively, met the composite endpoint; mean percent change from baseline in ALP was -37.1% and -10.1%, respectively. Upon rollover to ASSURE (13 seladelpar, 6 placebo), ALP declines were maintained for up to 18 months. An additional 35 patients with compensated cirrhosis in ASSURE from legacy studies had similar reductions in ALP with up to 2 years of treatment. Bilirubin remained overall stable. No treatment-related serious adverse events occurred. Variceal bleeding and/or ascites developed in 3 patients after ≥9 months. CONCLUSIONS: Seladelpar decreased markers of cholestasis and was overall safe and well-tolerated in patients with PBC and compensated cirrhosis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
FIGURE 1Proportion of patients with primary biliary cholangitis and compensated cirrhosis achieving the composite endpoint in the RESPONSE and ASSURE studies. (A) Proportion of patients with PBC and compensated cirrhosis in RESPONSE and upon rollover to ASSURE who achieved the composite endpoint. Months 13, 15, and 18 correspond to ASSURE months 1, 3, and 6. Month 12 RESPONSE data have been previously published. 32 (B) Proportion of patients with PBC and compensated cirrhosis in the ASSURE legacy group who achieved the composite endpoint. That composite endpoint was defined as ALP <1.67×ULN, ALP decrease ≥15% from baseline, and total bilirubin ≤ULN. Baseline was determined by the RESPONSE study entry for RESPONSE patients and the ASSURE study entry for legacy patients. Bars indicate 95% confidence interval. Abbreviations: ALP, alkaline phosphatase; CI, confidence interval; TB, total bilirubin; ULN, upper limit of normal.
非 KM Figure
FIGURE 2Mean percent change from baseline in markers of cholestasis and liver injury in patients with primary biliary cholangitis and compensated cirrhosis in the RESPONSE and ASSURE studies. (A) Mean percent change from baseline in ALP in patients with PBC and compensated cirrhosis in RESPONSE and upon rollover to ASSURE. (B) Mean percent change from baseline in ALP in patients with PBC and compensated cirrhosis in the ASSURE legacy group. (C) Mean percent change from baseline in GGT in patients with PBC and compensated cirrhosis in RESPONSE and upon rollover to ASSURE. (D) Mean percent change from baseline in GGT in patients with PBC and compensated cirrhosis in the ASSURE legacy group. (E) Mean percent change from baseline in ALT in patients with PBC and compensated cirrhosis in RESPONSE and upon rollover to ASSURE. (F) Mean percent change from baseline in ALT in patients with PBC and compensated cirrhosis in the ASSURE legacy group. For the RESPONSE graphs showing rollover to ASSURE, months 13, 15, and 18 correspond to ASSURE months 1, 3, and 6. Baseline was determined by the RESPONSE study entry for RESPONSE patients and the ASSURE study entry for legacy patients. Bars indicate standard error. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; BL, baseline; GGT, gamma-glutamyl transferase.
非 KM Figure